Fully Human Antibody / TCR Platforms

Bispecific Antibody

Bispecific antibodies (BsAbs) offer unique advantages by targeting two antigens simultaneously, enabling enhanced specificity, overcoming resistance, and addressing disease heterogeneity. They optimize pharmacokinetics, reduce off-target effects, and support diverse mechanisms such as pathway blockade and immune cell redirection, unlocking broad therapeutic potential.
  • The ability to simultaneously target multiple tumor-driven proteins, potentially overcoming drug resistance.
  • Recognition of cells co-expressing both targets to increase tumor specificity and reduce off-target toxicity.
  • The combination of two selected targets increases internalization and thus tumor killing.
  • 10+
    Fully-human BsAbs
  • 10+
    TCR mimic Assets
Request Data Package Schedule a Meeting
related resource

on this page

  • Advantages of Biocytogen's BsAb Platform
  • Discovery of Novel Bispecific Antibodies
  • Off-the-shelf BsAbs Available for Partnership

Webinars

View All

    Posters

    View All
      Advantages of Biocytogen's BsAb Platform
      • Versatile Design: Enables the assembly of diverse components like scFv, peptides, VHHs, and cytokines with flexible formats supported by technologies like Knobs-into-Holes.
      • Common Light Chain Advantage: Produces fully human common light chain antibodies for efficient and precise bispecific assembly with minimal mispairing.
      • High-Quality Antibodies: Combines RenLite KO mice and Beacon technology to generate antibodies with exceptional diversity and affinity.
      • Scalable Validation: Employs a robust in vivo system to identify effective and safe target combinations.
      • Bifunctional Molecules: Develops antibody-cytokine molecules with superior synergy, enhancing the druggability of cytokine-based therapies.
      Biocytogen's RenLite-based BsAb Platform

      BsAb developed from RenLite mice

      BsAb developed from RenLite mice
      Off-the-shelf BsAbs Available for Partnership
      Format Therapeutic Area Product Number Target(s) Immunization
      • Development
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND Phase I Status
      BsAb Oncology YH008 PD-1 x CD40
      		Partnered ex-China rights available
      BsAb Oncology YH006 OX40 x CTLA4
      BsAb Oncology BCG021 4-1BB x CD40
      BsAb Inflammation and Autoimmunity BCG028 OX40 x OX40
      BsAb Oncology - CD40 x CTLA4
      BsAb Oncology BCG051 GDF15 x VEGFA
      BsAb Inflammation and Autoimmunity - IL4RA x KIT
      BsAb Inflammation and Autoimmunity - IL13 x TSLP
      BsAb Inflammation and Autoimmunity - IL17A x IL17F x IL4RA
      BsAb Oncology - B7-H3 x FN1
      TCE Oncology - CD28 x CDH17 x CD3e
      TCE Oncology - STEAP1 x CD3e
      Tri-Ab Oncology BCG024 DLL3 x CD3E x 4-1BB
      Tri-Ab Oncology BCG038 EGFR x VEGFA x CD98
      Tri-Ab Oncology - PD-L1 x CD98 x VEGFA
      Tri-Ab Inflammation and Autoimmunity - C2 x FCGRT x ALB
      Tri-Ab Oncology - PD-L1 x IL11 x VEGFA
      Tri-Ab Oncology - PD-L1 x VEGFA x IL27R